RSCM
TVRD

Rock Springs Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Rock Springs Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4,167
Closed -$2.76M – 155
2017
Q1 		$2.76M Buy
+4,167
New +$2.23M 0.16% 113

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Rock Springs Capital Management's TVRD Position: Q2 2017 in Review

Rock Springs Capital Management sold out of Tvardi Therapeutics (TVRD) in Q2 2017, closing a stake of 4,167 shares — an estimated $2.76M sold.

Rock Springs Capital Management first reported a position in TVRD in Q1 2017 and held it in 1 quarter. The position peaked at $2.76M in Q1 2017. 127 funds tracked by Wall St. Rank hold TVRD as of Q2 2017.

  • Rock Springs Capital Management reported no remaining Tvardi Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Rock Springs Capital Management sold 4,167 Tvardi Therapeutics shares in Q2 2017, an estimated $2.76M.
  • Rock Springs Capital Management first reported a position in Tvardi Therapeutics in Q1 2017 and held it in 1 quarter.
  • Rock Springs Capital Management's Tvardi Therapeutics position peaked at $2.76M in Q1 2017.
  • 127 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2017.

Based on Rock Springs Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.